July 13, 2017 / 8:15 PM / 9 days ago

BRIEF-Janssen announces FDA approval of Tremfya

1 Min Read

July 13 (Reuters) - Johnson & Johnson

* Janssen announces U.S. FDA approval of Tremfya (guselkumab) for the treatment of moderate to severe plaque psoriasis

* Janssen says Tremfya demonstrated superior results in skin clearance compared with Humira in head-to-head analyses at weeks 16, 24 and 48

* Janssen- ‍seven out of ten patients receiving Tremfya achieved at least 90 percent improvement in skin clearance at week 16​

* Janssen says applications seeking approval in European union, Japan and other countries are currently under review Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below